Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 31.6
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Data is available to registered users only
Buy
Sell